GlassScriptPhysician profile
Hussam Farhoud
NPI 1144287574
$24,674.12
in general payments reported to CMS, 2019-2025
29 companies · $1,461 in 2025
The $1,461 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,751 · 2020: $984 · 2021: $2,351 · 2022: $5,443 · 2023: $3,828 · 2024: $3,855 · 2025: $1,461.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,351 · Travel and Lodging: $2,724 · Consulting Fee: $1,069.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,350.54 |
| Travel and Lodging | $2,724.45 |
| Consulting Fee | $1,068.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $7,764.31 | 2019-2025 | Aveir, Thoratec Heartmate 3 Lvas Implant Kit, Allure |
| Medtronic, INC. | $6,164.54 | 2021-2025 | Micra, Corevalve Evolut R, Azure Xt Dr Mri Surescan |
| Novartis Pharmaceuticals Corporation | $4,079.00 | 2019-2025 | |
| Medtronic Vascular, INC. | $2,058.56 | 2019-2020 | |
| Boston Scientific Corporation | $1,354.37 | 2019-2024 | |
| Abiomed | $930.37 | 2019-2025 | Impella |
| Pfizer INC. | $412.93 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $408.41 | 2019-2024 | Wainua, Farxiga |
| E.R. Squibb & Sons, L.L.C. | $243.66 | 2020-2025 | Camzyos, Eliquis |
| Janssen Pharmaceuticals, INC | $235.36 | 2019-2022 | |
| Endologix LLC | $172.64 | 2024 | Endocross Device, Torus Stent Graft System |
| Cvrx, INC. | $161.01 | 2022-2025 | Barostim Neo System |
| Tactile Systems Technology INC | $153.94 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $121.18 | 2019-2025 | Lifevest |
| Amgen INC. | $90.98 | 2019-2025 | Repatha, Repatha |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shockwave Medical, INC | $83.90 | 2021 | |
| Impulse Dynamics (USA) INC. | $58.40 | 2025 | Optimizer |
| Kestra Medical Technology Services, INC. | $26.36 | 2025 | Assure Wcd |
| Cook Medical LLC | $24.46 | 2024 | Zilver Ptx |
| Merck Sharp & Dohme LLC | $21.70 | 2022 | |
| Biotronik INC. | $20.83 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $18.37 | 2021 | |
| Kiniksa Pharmaceuticals, LTD. | $16.64 | 2023 | Arcalyst |
| Scpharmaceuticals INC. | $14.14 | 2024 | |
| Philips North America LLC | $13.24 | 2019 | |
| Surmodics, INC. | $12.98 | 2023 | Pounce Thrombectomy System, Pounce Venous Thrombectomy System, Pounce Thrombectomy |
| Sanofi-Aventis U.S. LLC | $11.84 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hussam Farhoud listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.